BIO 2022 Notebook: Deal Values In The Eyes Of The Beholders
Executive Summary
News and views from day 3 of the BIO annual meeting include business development insights, such as Sanofi's global head of BD Alban De La Sabliere's promise that big pharma has no hidden agenda and an AbbVie BD exec's observations that lower company valuations have not led to lower asking prices. Also, BIO chairman and Nkarta CEO Paul Hastings' optimism that biotech will rebound and Venus Williams' Sjogren's disease story draws a crowd.
You may also be interested in...
Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
2021 Deal Snapshot: Continued Emphasis On Bolt-Ons, Alliances Up
INFOGRAPHIC: M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.